Home›Clinical trials›Texas

GLP-1 clinical trials in Texas: 55 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

55 GLP-1 clinical trials are recruiting at 266 sites in 55 cities across Texas. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Texas

  1. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    The registry lists a near-identical study as NCT06857942.

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    8 sites in Texas
    • Precision Comprehensive Clinical Research Solutions - Colleyville, Colleyville. 9722998399
    • AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Fort Worth, Fort Worth. 817-789-6770
    • Accurate Clinical Research, Inc, Houston. 281-481-8557
    • Research Physicians Network, LLC, Houston. 281-944-3610
    • AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Irving, Irving
    • Biopharma Informatic, LLC, Katy. (281) 944-3610
    • Advanced Rheumatology of Houston - Woodlands, The Woodlands. 936-681-4882
    • DM Clinical Research - TRA, Tomball. 281-517-0550

    NCT06864026 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    The registry lists a near-identical study as NCT06864026.

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    6 sites in Texas

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in Texas

    • Premier Internal Medicine Associates of Houston, Katy. 281-398-8044
    • North Dallas Research Associates, McKinney. 972-529-6939

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  1. A study testing whether a GLP-1 medicine, semaglutide, can help people with spinal cord injuries lower blood sugar.

    Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

    Phase 4. Marzieh Salehi plans to enroll 50 participants.

    Who can join. Adults 18 to 70, have spinal cord injuries, BMI 22+.

    2 sites in Texas

    • University Health - Texas Diabetic Institute, San Antonio
    • University of Texas Health Science Center at San Antonio, San Antonio

    NCT06706284 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 medicine, semaglutide, can help people with prediabetes lower blood sugar.

    Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

    Phase 4. The University of Texas Health Science Center, Houston plans to enroll 300 participants.

    Who can join. Adults 18+, have prediabetes, BMI 30+.

    1 site in Texas

    • UTHealth Clinical Research Unit (CRU) at UT Brownsville, Brownsville. 956-755-0695

    NCT05119179 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    38 sites in Texas

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  4. A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    29 sites in Texas
    • American Research Corporation, Austin. 210-253-3426
    • IMA Clinical Research Austin, Austin. 512-649-0082
    • Pinnacle Clinical Research, Austin. 512-384-1460 x3001
    • Bellaire Clinical Research, Bellaire
    • Headlands Horizons, LLC dba Headlands Research-Brownsville, Brownsville
    • South Texas Research Institute - Brownsville, Brownsville. 956-468-3360
    • Soma Clinical Trials, Denison. 469-819-0228
    • Epic Medical Research - DeSoto, DeSoto. 197-277-7695
    • South Texas Research Institute, Edinburg. 956-468-3360
    • Dallas Research Institute, Farmers Branch. 214-347-7577
    • Care United Research, LLC, Forney. 972-564-0044
    • GI Alliance - Fort Worth, Fort Worth. 817-612-5575
    • Biopharma Informatic, LLC, Houston. 281-944-3610
    • Care Access - Houston, Houston. 877-791-0656
    • Houston Research Institute, Houston. 281-809-3234
    • HRI- Medical Center, Houston
    • Research Physicians Network, LLC, Houston. 281-944-3610
    • Biopharma Informatic, LLC, McAllen. 281-944-3610
    • DHR Health Institute for Research and Development (Administrative Office & Laboratory), McAllen. 956-362-2390
    • Southern Endocrinology Associates, Mesquite. 214-693-0904
    • HRI Pasadena, Pasadena. 832-847-1727
    • American Research Corporation at Texas Liver Institute, San Antonio. 210-253-3426
    • Clinical Trials of Texas, LLC dba Flourish Research, San Antonio. 210-949-0122
    • IMA Clinical Research San Antonio, San Antonio. 210-692-7157
    • Consano Clinical Research, LLC, Shavano Park. 210-545-4900
    • GI Alliance - Southlake, Southlake. 940-367-2316
    • Houston Research Institute (HRI) - Sugar Land, Sugar Land
    • Texas Valley Clinical Research, Weslaco. 956-431-8090
    • Medrasa Clinical Research, Wylie. 469-449-3645

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  5. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    27 sites in Texas

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  6. A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    Who can join. Adults 18+, have obesity, BMI 35+.

    19 sites in Texas
    • Amarillo Med Spec LLP, Amarillo
    • Texas Diab & Endo, P.A., Austin
    • Velocity Clinical Research Austin, Austin
    • North Texas Endocrine Center, Dallas
    • Velocity Clin Res, Dallas, Dallas
    • Cedar Health Research, Euless
    • JCCT- Juno NW Houston, Houston
    • The Endocrine Center, Houston
    • Medical Colleagues-Texas LLP, Katy
    • Sante Clinical Research, Kerrville
    • Radiance Clinical Research, Lampasas
    • Aeres Clinical Research, Laredo
    • DCOL Ctr for Clin Res, Longview
    • RGV Endocrine Center, McAllen
    • AES San Antonio, San Antonio
    • Northeast Clinical Research of San Antonio, San Antonio
    • Quality Research Inc, San Antonio
    • Consano Clinical Research, LLC, Shavano Park
    • Mt Olympus Medical Research, LLC, Sugar Land

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  7. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    13 sites in Texas

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

The other 45 studies recruiting in Texas

  1. A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Amgen plans to enroll 300 participants.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    8 sites in Texas
    • Epic Medical Research - DeSoto, DeSoto
    • South Texas Research Institute, Edinburg
    • Biopharma Informatic, LLC, Houston
    • Research Physicians Network, LLC, Houston
    • Texas Institute of Cardiology, McKinney
    • North Hills Medical Research, North Richland Hills
    • VIP Trials, San Antonio
    • Northwest Houston Heart Center, Tomball

    NCT07575399 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    Who can join. Children and teens 6 to 17, have obesity.

    6 sites in Texas
    • Dell Children's Medical Center - PIN, Austin
    • Driscoll Children's Hospital, Corpus Christi
    • Dynamed Clinical Research, LP d/b/a DM Clinical Research, Houston. 281-517-0550
    • La Providence Pediatrics Clinic - Chemidox Clinical Trials, Houston. 833-324-3643
    • McGovern Medical School, Houston
    • Martin Diagnostic Clinic, Tomball. 281-517-0550

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 460 participants.

    Who can join. Children and teens 8 to 18, are overweight.

    6 sites in Texas
    • DM Clinical, Houston
    • DM Clinical, San Antonio
    • Pinnacle Clinical Research, San Antonio
    • The Texas Liver Institute, San Antonio
    • Consano Clin Res-Shavano Park, Shavano Park
    • Texas Valley Clinical Research, Weslaco

    NCT07253285 on ClinicalTrials.gov. See whether you qualify.

  4. A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    6 sites in Texas
    • Research Site, Dallas
    • Research Site, Houston
    • Research Site, Katy
    • Research Site, San Antonio
    • Research Site, Sugar Land
    • Research Site, Weslaco

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

  5. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people lose weight.

    A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

    Phase 3. Eli Lilly and Company plans to enroll 300 participants.

    Who can join. Children and teens 12 to 17, have obesity.

    5 sites in Texas
    • Driscoll Children's Hospital, Corpus Christi
    • Epic Medical Research - DeSoto, DeSoto
    • Valley Institute of Research - Fort Worth, Fort Worth
    • Consano Clinical Research, LLC, Shavano Park
    • Texas Valley Clinical Research, Weslaco

    NCT06439277 on ClinicalTrials.gov. See whether you qualify.

  6. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    5 sites in Texas

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  7. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Eli Lilly and Company plans to enroll 1,205 participants.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    4 sites in Texas

    • Biopharma Informatic, LLC, Houston. 281-944-3610
    • Research Physicians Network, LLC, Houston. 832-847-1724
    • Sherman Clinical Research, Sherman. 903-771-4093
    • NextStage Clinical Research - Waco, Waco

    NCT07223593 on ClinicalTrials.gov. See whether you qualify.

  8. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Eli Lilly and Company plans to enroll 150 participants.

    Who can join. Children and teens 12 to 17, have obesity.

    3 sites in Texas

    • Dynamed Clinical Research, LP d/b/a DM Clinical Research, Houston
    • La Providence Pediatrics Clinic - Chemidox Clinical Trials, Houston
    • Martin Diagnostic Clinic, Tomball

    NCT06672939 on ClinicalTrials.gov. See whether you qualify.

  9. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    3 sites in Texas

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  10. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Eli Lilly and Company plans to enroll 290 participants.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    3 sites in Texas

    NCT06937099 on ClinicalTrials.gov. See whether you qualify.

  11. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with type 2 diabetes lower blood sugar.

    Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

    Phase 3. The University of Texas Health Science Center at San Antonio plans to enroll 256 participants.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    2 sites in Texas

    • University Health System Texas Diabetic Institute, San Antonio. 210-567-2391
    • UT Health Science Center, San Antonio

    NCT06246799 on ClinicalTrials.gov. See whether you qualify.

  12. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Eli Lilly and Company plans to enroll 1,000 participants.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    2 sites in Texas

    • Innovative Medical Research of Texas, Houston
    • Next Level Urgent Care, Houston. 832-460-3311

    NCT07202884 on ClinicalTrials.gov. See whether you qualify.

  13. A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. VA Office of Research and Development plans to enroll 622 participants.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    2 sites in Texas

    • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas. 214-857-0125
    • Michael E. DeBakey VA Medical Center, Houston, TX, Houston. 713-798-7658

    NCT07218354 on ClinicalTrials.gov. See whether you qualify.

  14. A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Kailera plans to enroll 1,200 participants.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Texas

    • Kailera Clinical Site, Brownsville
    • Kailera Clinical Site, San Antonio

    NCT07284979 on ClinicalTrials.gov. See whether you qualify.

  15. A study testing whether an investigational medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

    A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Phase 3. Vanda Pharmaceuticals plans to enroll 280 participants.

    Who can join. Adults 18 to 65, have nausea and vomiting, BMI 25+.

    2 sites in Texas

    NCT07446439 on ClinicalTrials.gov. See whether you qualify.

  16. A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 450 participants.

    Who can join. Adults 18+, are overweight, BMI 27+.

    1 site in Texas

    • Cedar Health Research, Dallas

    NCT07770841 on ClinicalTrials.gov. See whether you qualify.

  17. A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    7 sites in Texas
    • IMA Clinical Research Austin, Austin. 512-649-0082
    • FutureSearch Trials of Dallas, Dallas. 214-369-2600
    • Velocity Clinical Research, Dallas, Dallas
    • PlanIt Research, PLLC, Houston. 713-973-3415
    • Endeavor Clinical Trials, San Antonio. 518-428-6859
    • Tekton Research - Fredericksburg Road, San Antonio
    • Texas Valley Clinical Research, Weslaco. 956-431-8090

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

  18. A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 300 participants.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    6 sites in Texas
    • IMA Clinical Research, Austin
    • Private Practice - Dr. Laila A. Hassan, Houston
    • Radiance Clinical Research, Lampasas
    • Quality Research Inc, San Antonio
    • Tekton Research Inc, San Antonio
    • Consano Clin Res-Shavano Park, Shavano Park

    NCT07668388 on ClinicalTrials.gov. See whether you qualify.

  19. A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Eli Lilly and Company plans to enroll 240 participants.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    5 sites in Texas

    NCT06897475 on ClinicalTrials.gov. See whether you qualify.

  20. A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Biomea Fusion Inc plans to enroll 60 participants.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    5 sites in Texas
    • Elligo Health Research, Inc., Austin
    • Zenos Clinical Research, Dallas
    • Synergy Group Medical, Houston
    • Epic Clinical Research, Lewisville
    • Diabetes & Glandular Disease Clinic, P.A., San Antonio

    NCT07502508 on ClinicalTrials.gov. See whether you qualify.

  21. A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Novo Nordisk A/S plans to enroll 465 participants.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    3 sites in Texas

    • Davita Clinical Research, El Paso
    • Clinical Advancement Center, San Antonio
    • Tekton Research, San Antonio

    NCT06717698 on ClinicalTrials.gov. See whether you qualify.

  22. A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 270 participants.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    3 sites in Texas

    • University of Texas Southwestern Medical Center, Dallas
    • JCCT- Juno NW Houston, Houston
    • Consano Clinical Research, LLC, Shavano Park

    NCT07415954 on ClinicalTrials.gov. See whether you qualify.

  23. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

    Phase 2. Regeneron Pharmaceuticals plans to enroll 204 participants.

    Who can join. Adults 18 to 75, have fatty liver disease (MASLD), BMI 30+.

    3 sites in Texas

    • American Research Corporation, Austin
    • Advanced Medical Trials, Georgetown
    • American Research Corporation at The Texas Liver Institute, San Antonio

    NCT07527910 on ClinicalTrials.gov. See whether you qualify.

  24. A study testing whether a GLP-1 medicine, semaglutide, can help people trying to quit smoking lose weight.

    Semaglutide for Post-Smoking Cessation Weight Management

    Phase 2. The University of Texas Health Science Center, Houston plans to enroll 197 participants.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    2 sites in Texas

    • The University of Texas at Austin, Austin. 573-825-2620
    • The University of Texas Health Science Center at Houston, Houston. 713-486-2737

    NCT06173778 on ClinicalTrials.gov. See whether you qualify.

  25. A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Novo Nordisk A/S plans to enroll 230 participants.

    Who can join. Adults 18+, have obesity, BMI 30+.

    2 sites in Texas

    • PlanIt Research, PLLC, Houston
    • Pinnacle Clinical Research, San Antonio

    NCT07639021 on ClinicalTrials.gov. See whether you qualify.

  26. A study testing whether a GLP-1 and GIP medicine, tirzepatide, may help during breast cancer treatment.

    Tirzepatide Weight Loss for MRD+ Early Breast Cancer

    Phase 2. Baylor Research Institute plans to enroll 48 participants.

    Who can join. Adults 18+, have breast cancer, BMI 27+.

    1 site in Texas

    • Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas. 214-820-5424

    NCT06517212 on ClinicalTrials.gov. See whether you qualify.

  27. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people lose weight.

    Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

    Phase 2. The University of Texas Health Science Center at San Antonio plans to enroll 20 participants.

    Who can join. Adults 50+, have obesity, BMI 30+.

    1 site in Texas

    • University of Texas Health Science Center at San Antonio, San Antonio

    NCT06811324 on ClinicalTrials.gov. See whether you qualify.

  28. A study testing whether a GLP-1 and GIP medicine, tirzepatide, affects healthy aging.

    Tirzepatide to Slow Biological Aging

    Phase 2. The University of Texas Medical Branch, Galveston plans to enroll 90 participants.

    Who can join. Adults 55 to 70, have aging, BMI 27+.

    1 site in Texas

    NCT07220473 on ClinicalTrials.gov. See whether you qualify.

  29. A study of a GLP-1 and GIP medicine, tirzepatide, in people with heart failure with preserved ejection fraction.

    Tailored Exercise Training Study Among Adults With HFpEF

    Phase 2. University of Texas Southwestern Medical Center plans to enroll 120 participants.

    Who can join. Adults 18+, have heart failure with preserved ejection fraction.

    1 site in Texas

    • University of Texas Southwestern Medical Center, Dallas. 214-645-9868

    NCT07223242 on ClinicalTrials.gov. See whether you qualify.

  30. A study of a GLP-1 medicine, semaglutide, in people with cocaine use disorder.

    Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

    Phase 2. The University of Texas Health Science Center, Houston plans to enroll 75 participants.

    Who can join. Adults 18+, have cocaine use disorder, BMI 25+.

    1 site in Texas

    • The University of Texas Health Science Center at Houston, Houston. 713-486-2737

    NCT07227948 on ClinicalTrials.gov. See whether you qualify.

  31. A study of a GLP-1 medicine, semaglutide.

    Incretin Microdosing for Cardiometabolic Health in People With HIV

    Phase 2. The University of Texas Health Science Center, Houston plans to enroll 30 participants.

    Who can join. Adults 18+, have weight gain, BMI 27+.

    1 site in Texas

    • The University of Texas Health Science Center at Houston, Houston. 713-500-6767

    NCT07325500 on ClinicalTrials.gov. See whether you qualify.

  32. A study of a study medicine, Exendin-(9-39), in people with hypoglycemia.

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

    Phase 1. The University of Texas Health Science Center at San Antonio plans to enroll 160 participants.

    Who can join. Adults 18 to 65, have hypoglycemia.

    2 sites in Texas

    • South Texas Veterans Health Care System, San Antonio. 210-567-6691
    • Texas Diabetes Institute - University Health System, San Antonio. 210-450-8696

    NCT00992901 on ClinicalTrials.gov. See whether you qualify.

  33. A study of a study medicine, exendin-(9-39).

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

    Phase 1. The University of Texas Health Science Center at San Antonio plans to enroll 80 participants.

    2 sites in Texas

    • South Texas Veterans Health Care System, San Antonio. 210-567-6691
    • Texas Diabetes Institute - University Health System, San Antonio. 210-450-8696

    NCT01803451 on ClinicalTrials.gov. See whether you qualify.

  34. A study of a study medicine, Exendin-(9-39).

    The Effects of Bariatric Surgeries on Glucose Metabolism

    Phase 1. The University of Texas Health Science Center at San Antonio plans to enroll 200 participants.

    2 sites in Texas

    • South Texas Veterans Health Care System, San Antonio. 210-567-6691
    • Texas Diabetes Institute - University Health System, San Antonio. 210-567-6691

    NCT02823665 on ClinicalTrials.gov. See whether you qualify.

  35. A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse

    Phase 1. Novo Nordisk A/S plans to enroll 114 participants.

    Who can join. Adults 18+, have obesity, BMI 30+.

    2 sites in Texas

    • Amarillo Medical Specialists, Amarillo
    • Elligo Clin Res Centre, Austin

    NCT07607587 on ClinicalTrials.gov. See whether you qualify.

  36. A study testing whether a GLP-1 medicine, semaglutide, can help people with prediabetes lower blood sugar and lose weight.

    Prevention of Progression of Prediabetes, Obesity and CV Risk

    Phase 1. The University of Texas Health Science Center at San Antonio plans to enroll 64 participants.

    Who can join. Adults 18+, have prediabetes, BMI 25+.

    1 site in Texas

    • University of Texas Health Science Center at San Antonio, San Antonio. 210-567-4900

    NCT06446531 on ClinicalTrials.gov. See whether you qualify.

  37. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with diabetes lower blood sugar.

    Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot

    Phase 1. M.D. Anderson Cancer Center plans to enroll 30 participants.

    Who can join. Adults 18+, have diabetes, BMI 27+.

    1 site in Texas

    • The University of Texas M. D. Anderson Cancer Center, Houston. 713-792-3250

    NCT06759701 on ClinicalTrials.gov. See whether you qualify.

  38. A study of a GLP-1 medicine, semaglutide, in people with Alzheimer's dementia (AD).

    Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

    Phase 1. The Methodist Hospital Research Institute plans to enroll 30 participants.

    Who can join. Adults 50 to 86, have Alzheimer's dementia (AD).

    1 site in Texas

    NCT07651319 on ClinicalTrials.gov. See whether you qualify.

  39. A study testing whether an investigational medicine from Novo Nordisk, NNC0721-8060, can help people lose weight.

    A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

    Phase 1. Novo Nordisk A/S plans to enroll 142 participants.

    Who can join. Adults 18 to 55, are overweight, BMI 27+.

    1 site in Texas

    • ICON, San Antonio

    NCT07767175 on ClinicalTrials.gov. See whether you qualify.

  40. A study listed on ClinicalTrials.gov.

    Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)

    University of Texas at Austin plans to enroll 75 participants.

    Who can join. Adults 30 to 60, women only, have obesity, BMI 25+.

    2 sites in Texas

    NCT07480109 on ClinicalTrials.gov. See whether you qualify.

  41. A study listed on ClinicalTrials.gov.

    Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor

    The University of Texas Health Science Center, Houston plans to enroll 136 participants.

    1 site in Texas

    • The University of Texas Health Science Center at Houston, Houston. (713) 500-6202

    NCT06654219 on ClinicalTrials.gov. See whether you qualify.

  42. A study of a GLP-1 medicine, semaglutide, in people with mild autonomous cortisol secretion (MACS).

    IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

    University of Texas Southwestern Medical Center plans to enroll 75 participants.

    Who can join. Adults 18+, have mild autonomous cortisol secretion (MACS), BMI 27+.

    1 site in Texas

    • University of Texas Southwestern Medical Center, Dallas. 2146456397

    NCT07361874 on ClinicalTrials.gov. See whether you qualify.

  43. A study of a GLP-1 and GIP medicine, tirzepatide, in people with substance use disorders.

    Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

    The University of Texas at Dallas plans to enroll 40 participants.

    Who can join. Adults 18 to 70, have substance use disorders.

    1 site in Texas

    NCT07387796 on ClinicalTrials.gov. See whether you qualify.

  44. A study in people with obesity or overweight.

    Tirzepatide Impact Assessment Study

    Texas Tech University plans to enroll 27 participants.

    Who can join. Adults 18+, have obesity or are overweight, BMI 27.5+.

    1 site in Texas

    • Nutrition Metabolic Health Initiative (NMHI), Lubbock. +18068342286

    NCT07740291 on ClinicalTrials.gov. See whether you qualify.

  45. A study listed on ClinicalTrials.gov.

    The GLOW Study: GLP-1 and Lifestyle for Optimal Wellness

    Saundra Jain plans to enroll 200 participants.

    1 site in Texas

    NCT07760896 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Check price →

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.